- Eleven abstracts accepted for poster presentation highlight
company’s differentiated antibody drug conjugate, multispecific
antibody, and clinical product candidates
- Management will host a conference call on April 18th at 6:30 pm
Eastern Standard Time (EST)
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology
company developing novel, multifunctional biotherapeutics, today
announced the acceptance of eleven abstracts for poster
presentation at the upcoming American Association for Cancer
Research (AACR) Annual Meeting taking place at the Orange County
Convention Center in Orlando, FL from April 14 – 19, 2023.
“AACR represents an important opportunity for us to share recent
progress in developing the next generation of novel therapeutics
and highlights the unique capabilities of our proprietary
engineering platforms and integrated technologies,” stated Paul
Moore, Ph.D., Chief Scientific Officer at Zymeworks. “The
acceptance of eleven abstracts reflects the rapid progress we have
made in developing our robust and differentiated pipeline. During
the meeting we look forward to sharing new preclinical data on our
anticipated 2024 IND candidates, ZW171 and ZW191, as well as other
programs that represent potential future therapeutic opportunities
and areas of interest.”
Presentation Details
Antibody Drug Conjugates
Title: Revisiting the dogma of antibody drug conjugates (ADCs):
Emerging data challenge the benefit of linker stability and the
primacy of payload delivery Abstract: 1538 Session Category:
Experimental and Molecular Therapeutics Session Title: Antibody
Drug Conjugates
Title: ZW191, a novel FRa-targeting antibody drug conjugate
bearing a topoisomerase 1 inhibitor payload Abstract: 2641 Session
Category: Experimental and Molecular Therapeutics Session Title:
Antibody Technologies
Title: ZW220, a novel NaPi2b-targeting antibody drug conjugate
bearing a topoisomerase 1 inhibitor payload Abstract: 1533 Session
Category: Experimental and Molecular Therapeutics Session Title:
Antibody Drug Conjugates
Title: ZW251, a novel glypican-3-targeting antibody drug
conjugate bearing a topoisomerase 1 inhibitor payload Abstract:
2658 Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody Technologies
Multispecific Antibody Therapeutics
Title: ZW171, a T cell-engaging, bispecific antibody for the
treatment of mesothelin-expressing solid tumors Abstract: 2942
Session Category: Immunology Session Title: Therapeutic Antibodies
2
Title: TriTCE Co-stim, next generation costimulatory trispecific
T cell engagers for the treatment of solid tumors Abstract: 5121
Session Category: Immunology Session Title: Combination
Immunotherapies 2
Title: TriTCE CPI, next generation trispecific T cell engagers
with integrated checkpoint inhibition (CPI) for the treatment of
solid tumors Abstract: 2982 Session Category: Immunology Session
Title: Therapeutic Antibodies 3
Title: PROTECT™, a novel trispecific antibody masking platform
with integrated immune modulation displays unique activity and
differentiated modes of action Abstract: 2926 Session Category:
Immunology Session Title: Therapeutic Antibodies 2
Title: ZW270, a conditionally masked IL-12 cytokine fusion
protein displaying potent anti-tumor activity absent systemic
toxicity Abstract: 2935 Session Category: Immunology Session Title:
Therapeutic Antibodies 2
Clinical Product Candidates
Title: ERBB2 amplification detected in ctDNA as a surrogate for
tumor tissue FISH analysis of HER2 status in a phase 1, study with
zanidatamab for the treatment of locally advanced or metastatic
HER2 expressing cancers Abstract: CT2781 Session Category: Clinical
Trials Posters Session Title: Phase I Clinical Trials 2
Title: Zanidatamab zovodotin (ZW49) induces hallmarks of
immunogenic cell death and is active in patient-derived xenograft
models of gastric cancer Abstract: 2633 Session Category:
Experimental and Molecular Therapeutics Session Title: Antibody
Technologies
Abstracts can be found on AACR’s website located at
www.aacr.org. Posters will be available at the time of presentation
at the conference on the Company's website located at
www.zymeworks.com.
1 Clinical trials abstract texts are
embargoed until noon ET on April 14, 2023
Conference Call and Webcast Information:
Zymeworks management will host a conference call and webcast for
investors and analysts on April 18, 2023, at 6:30 pm EST. The event
will be webcast live with dial-in details and webcast replays
available on Zymeworks’ website at
http://ir.zymeworks.com/events-and-presentations.
About Zymeworks Inc.
Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company
committed to the discovery, development, and commercialization of
novel, multifunctional biotherapeutics. Zymeworks' mission is to
make a meaningful difference for people impacted by
difficult-to-treat cancers and other serious diseases. Zymeworks'
complementary therapeutic platforms and fully integrated drug
development engine provide the flexibility and compatibility to
precisely engineer and develop highly differentiated antibody-based
therapeutic candidates. Zymeworks engineered and developed
zanidatamab, a HER2-targeted bispecific antibody using Zymeworks'
proprietary Azymetric™ technology. Zymeworks has entered into
separate agreements with BeiGene, Ltd. (BeiGene) and Jazz
Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene
and Jazz with exclusive rights to develop and commercialize
zanidatamab in different territories. Zanidatamab is currently
being evaluated in global Phase 1, Phase 2, and Phase 3 clinical
trials, including certain ongoing pivotal clinical trials as a
treatment for patients with HER2-expressing cancers. Zymeworks'
next clinical candidate, zanidatamab zovodotin (ZW49), is a
HER2-targeted bispecific antibody-drug conjugate (ADC) developed
using Zymeworks' proprietary Azymetric™ and ZymeLink™ Auristatin
technologies. Zanidatamab zovodotin is currently being evaluated in
a Phase 1 clinical trial for patients with a variety of
HER2-expressing, HER2-amplified or HER2-mutant cancers. Zymeworks
is also advancing a deep pipeline of product candidates based on
its experience and capabilities in both ADC and multispecific
antibodies (MSAT). In addition to Zymeworks' wholly owned pipeline,
its therapeutic platforms have been further leveraged through
strategic partnerships with global biopharmaceutical companies. For
information about Zymeworks, visit www.zymeworks.com and follow
@ZymeworksInc on Twitter.
Cautionary Note Regarding Forward-Looking Statements
This press release includes “forward-looking statements” or
information within the meaning of the applicable securities
legislation, including Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. Forward-looking statements in this press release
include, but are not limited to, statements that relate to
Zymeworks’ preclinical pipeline; the potential therapeutic effects
of zanidatamab and Zymeworks’ other product candidates; Zymeworks’
clinical development of its product candidates and enrollment in
its clinical trials; anticipated preclinical and clinical data
presentations; the ability to advance product candidates into later
stages of development; and other information that is not historical
information. When used herein, words such as “plan”, “believe”,
“expect”, “may”, “anticipate”, “potential”, “will”, “continues”,
and similar expressions are intended to identify forward-looking
statements. In addition, any statements or information that refer
to expectations, beliefs, plans, projections, objectives,
performance or other characterizations of future events or
circumstances, including any underlying assumptions, are
forward-looking. All forward-looking statements are based upon
Zymeworks’ current expectations and various assumptions. Zymeworks
believes there is a reasonable basis for its expectations and
beliefs, but they are inherently uncertain. Zymeworks may not
realize its expectations, and its beliefs may not prove
correct.
Actual results could differ materially from those described or
implied by such forward-looking statements as a result of various
factors, including, without limitation: future clinical trials may
not demonstrate safety and efficacy of any of Zymeworks’ or its
collaborators’ product candidates; clinical trials may not
demonstrate safety and efficacy of any of Zymeworks’ or its
collaborators’ product candidates; any of Zymeworks’ or its
partners’ product candidates may fail in development, may not
receive required regulatory approvals, or may be delayed to a point
where they are not commercially viable; regulatory agencies may
impose additional requirements or delay the initiation of clinical
trials; the impact of the COVID-19 pandemic on Zymeworks’ business,
research and clinical development plans and timelines and results
of operations, including impact on its clinical trial sites,
collaborators, and contractors who act for or on Zymeworks’ behalf,
may be more severe and more prolonged than currently anticipated;
the impact of new or changing laws and regulations; market
conditions; inability to maintain or enter into new partnerships or
strategic collaborations; and the factors described under “Risk
Factors” in Zymeworks’ quarterly and annual reports filed with the
Securities and Exchange Commission, including its Annual Report on
Form 10-K for its year ended December 31, 2022 (a copy of which may
be obtained at www.sec.gov and
www.sedar.com).
Although Zymeworks believes that such forward-looking statements
are reasonable, there can be no assurance they will prove to be
correct. Investors should not place undue reliance on
forward-looking statements. The above assumptions, risks and
uncertainties are not exhaustive. Forward-looking statements are
made as of the date hereof and, except as may be required by law,
Zymeworks undertakes no obligation to update, republish, or revise
any forward-looking statements to reflect new information, future
events or circumstances, or to reflect the occurrences of
unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230314005744/en/
Investor Inquiries: Jack Spinks Director, Investor Relations
(604) 678-1388 ir@zymeworks.com Media Inquiries: Diana Papove
Director, Corporate Communications (604) 678-1388
media@zymeworks.com
Zymeworks (NASDAQ:ZYME)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zymeworks (NASDAQ:ZYME)
Historical Stock Chart
From Jul 2023 to Jul 2024